FY2024 Earnings Estimate for Option Care Health, Inc. Issued By William Blair (NASDAQ:OPCH)

Option Care Health, Inc. (NASDAQ:OPCH) – Equities researchers at William Blair upped their FY2024 earnings estimates for Option Care Health in a report issued on Wednesday, April 24th. William Blair analyst M. Larew now forecasts that the company will post earnings per share of $1.19 for the year, up from their prior forecast of $1.17. The consensus estimate for Option Care Health’s current full-year earnings is $1.13 per share. William Blair also issued estimates for Option Care Health’s Q1 2025 earnings at $0.30 EPS, Q2 2025 earnings at $0.35 EPS, Q4 2025 earnings at $0.41 EPS and FY2025 earnings at $1.43 EPS.

Several other equities analysts have also recently weighed in on OPCH. Barrington Research reiterated an “outperform” rating and set a $38.00 price objective on shares of Option Care Health in a research report on Wednesday. Jefferies Financial Group lifted their price objective on shares of Option Care Health from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, March 4th.

Option Care Health Trading Down 2.1 %

Option Care Health stock opened at $29.29 on Thursday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.33 and a current ratio of 1.77. The firm has a market cap of $5.09 billion, a price-to-earnings ratio of 19.27, a price-to-earnings-growth ratio of 1.74 and a beta of 1.22. Option Care Health has a 1 year low of $24.23 and a 1 year high of $35.74. The firm’s 50 day moving average price is $32.04 and its two-hundred day moving average price is $31.50.

Option Care Health (NASDAQ:OPCH) last posted its quarterly earnings data on Tuesday, April 23rd. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.04. The business had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.10 billion. Option Care Health had a net margin of 6.15% and a return on equity of 18.92%. The business’s revenue for the quarter was up 12.8% on a year-over-year basis. During the same quarter last year, the business earned $0.21 earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Principal Securities Inc. bought a new position in shares of Option Care Health during the 4th quarter worth about $27,000. Parallel Advisors LLC increased its holdings in shares of Option Care Health by 130.2% during the 4th quarter. Parallel Advisors LLC now owns 845 shares of the company’s stock worth $28,000 after purchasing an additional 478 shares during the period. TFO Wealth Partners LLC increased its holdings in shares of Option Care Health by 24,625.0% during the 4th quarter. TFO Wealth Partners LLC now owns 989 shares of the company’s stock worth $33,000 after purchasing an additional 985 shares during the period. Park Place Capital Corp increased its holdings in shares of Option Care Health by 48.4% during the 1st quarter. Park Place Capital Corp now owns 1,140 shares of the company’s stock worth $38,000 after purchasing an additional 372 shares during the period. Finally, First Horizon Advisors Inc. bought a new stake in Option Care Health in the third quarter valued at about $37,000. Institutional investors own 98.05% of the company’s stock.

Insider Activity at Option Care Health

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. acquired 35,000 shares of Option Care Health stock in a transaction that occurred on Monday, February 26th. The stock was acquired at an average price of $31.55 per share, with a total value of $1,104,250.00. Following the purchase, the director now owns 269,528 shares in the company, valued at $8,503,608.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.64% of the stock is owned by company insiders.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.